NCT04809155 (G2G) is a NA clinical trial of Girl2Girl in Pregnancy Prevention, sponsored by Center for Innovative Public Health Research.

Who is sponsoring NCT04809155?

NCT04809155 is sponsored by Center for Innovative Public Health Research.

What drugs are being tested in NCT04809155?

Interventions in NCT04809155: Girl2Girl.

What condition does NCT04809155 study?

NCT04809155 studies Pregnancy Prevention.

Is NCT04809155 still recruiting?

NCT04809155 is currently status unknown. Last updated 22 March 2021.

Last reviewed 2021-03-22 · How we verify

NCT04809155: G2G

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Girl2Girl: A Web-based Trial

Status unknown NA Last updated 22 March 2021

What this trial tests

NA trial testing Girl2Girl in Pregnancy Prevention in 574 participants. Status unknown.

Timeline

7 July 2020

Primary endpoint
7 June 2021

7 June 2021

Quick facts

Lead sponsor	Center for Innovative Public Health Research
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	574
Start date	7 July 2020
Primary completion	7 June 2021
Estimated completion	7 June 2021
Sites	1 location across United States

Drugs / interventions tested

Girl2Girl

Conditions studied

Pregnancy Prevention — all drugs for Pregnancy Prevention →

Sponsor

Center for Innovative Public Health Research

Who can join

Adults 14 to 18, female only, with Pregnancy Prevention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot effectiveness study of Girl2Girl, a text messaging-based pregnancy prevention program for cisgender sexual minority adolescents.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pregnancy Prevention

Currently open trials in the same condition.

NCT06306131 — Phase II Study of Ovulation in Obese Women · Phase 2 · recruiting
NCT05695352 — Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days · Phase 2 · recruiting

Other Center for Innovative Public Health Research trials

Trials by the same sponsor.

NCT06586151 — Testing a Gender-inclusive HIV Prevention Program · NA · recruiting
NCT06230367 — Sexual Health Advocacy for Guys - a Text Messaging-based HIV Prevention Program for Guys Who Are Into Guys · NA · recruiting
NCT06017050 — BullyDown, a Text Messaging-based Bullying Prevention Program for Middle School-aged Youth · NA · completed
NCT02819349 — Texting for Relapse Prevention · NA · completed
NCT02729337 — Affecting the Epidemiology of HIV in Uganda · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04809155 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Center for Innovative Public Health Research
Last refreshed: 22 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04809155.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing